1. Home
  2. MKTX vs GKOS Comparison

MKTX vs GKOS Comparison

Compare MKTX & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MarketAxess Holdings Inc.

MKTX

MarketAxess Holdings Inc.

HOLD

Current Price

$176.86

Market Cap

6.0B

Sector

Finance

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$120.70

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MKTX
GKOS
Founded
2000
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
6.0B
IPO Year
2004
2015

Fundamental Metrics

Financial Performance
Metric
MKTX
GKOS
Price
$176.86
$120.70
Analyst Decision
Buy
Strong Buy
Analyst Count
8
14
Target Price
$206.29
$133.07
AVG Volume (30 Days)
366.2K
653.9K
Earning Date
05-06-2026
04-29-2026
Dividend Yield
1.78%
N/A
EPS Growth
N/A
N/A
EPS
6.64
N/A
Revenue
$397,471,000.00
$507,442,000.00
Revenue This Year
$9.91
$23.30
Revenue Next Year
$7.38
$27.43
P/E Ratio
$26.48
N/A
Revenue Growth
7.45
32.33
52 Week Low
$156.17
$73.16
52 Week High
$232.84
$130.23

Technical Indicators

Market Signals
Indicator
MKTX
GKOS
Relative Strength Index (RSI) 56.05 64.03
Support Level $159.39 $81.54
Resistance Level $183.23 $123.16
Average True Range (ATR) 4.76 4.63
MACD 0.90 2.02
Stochastic Oscillator 79.15 88.93

Price Performance

Historical Comparison
MKTX
GKOS

About MKTX MarketAxess Holdings Inc.

Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: